Base editing of Artemis mutations ex vivo sheds light on gene therapy for Artemis-deficient SCID
Open Access
- 15 May 2026
- journal article
- research article
- Published by Springer Nature in Advanced Biotechnology
- Vol. 4 (2) , 20
Abstract
Artemis is an endonuclease that cleaves DNA hairpins during V(D)J recombination, a critical step enabling coding-joint formation and essential for lymphocyte development. Artemis-deficient severe combined immunodeficiency (ART-SCID) is a monogenic disorder marked by impaired lymphocyte development and poor responsiveness to allogeneic hematopoietic stem cell transplantation. In this study, we explored the use of base editors to correct mutations in the Artemis gene. Specifically, we firstly documented the pathogenic mutations of Artemis from previous studies and newly identified from ClinVar database. Then, we performed ex vivo assays using cytidine base editors (CBEs) to repair the c.181T > C mutation, and adenosine base editors (ABEs) to target the pathogenic c.49G > A and c.404G > A variants associated with ART-SCID. Targeted deep sequencing revealed that rAPOBEC1-SpRY-HF1-BE4max achieved efficient editing (~ 50%) at the c.181T > C site, while ABE8e reached ~ 35% and ~ 20% editing efficiency at the c.49G > A and c.404G > A sites, respectively. Importantly, base editors restored Artemis endonuclease activity in a 293T Artemis −/− system, with no detectable off-target effects at the predicted sites as assessed by targeted deep sequencing. These findings provide proof-of-concept that base editing can correct ART-SCID-associated mutations, highlighting its potential for future therapeutic development.Keywords
Funding Information
- Guangdong S&T Program (2024B1111130003)
- Guangdong S&T Program (2024B1515040009)
- Guangdong S&T Program (2023B1212060028)
- National Natural Science Foundation of China (32170888)
- National Natural Science Foundation of China (32500788)
This publication has 59 references indexed in Scilit:
- Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editingCell, 2023
- Clinical and Genetic Characterization of Patients with Artemis Deficiency in JapanJournal of Clinical Immunology, 2022
- Enhanced prime editing systems by manipulating cellular determinants of editing outcomesCell, 2021
- Compound heterozygous DCLRE1C mutations lead to clinically typical Severe Combined Immunodeficiency presenting with Graft Versus Host DiseaseImmunogenetics, 2021
- Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor CellsCell Reports, 2020
- Severe combined immunodeficiency (SCID) presenting in childhood, with agammaglobulinemia, associated with novel compound heterozygous mutations in DCLRE1CClinical Immunology, 2019
- The many faces of Artemis-deficient combined immunodeficiency — Two patients with DCLRE1C mutations and a systematic literature review of genotype–phenotype correlationClinical Immunology, 2013
- The most frequentDCLRE1C(ARTEMIS) mutations are based on homologous recombination eventsHuman Mutation, 2009
- Defective Artemis nuclease is characterized by coding joints with microhomology in long palindromic‐nucleotide stretchesEuropean Journal of Immunology, 2007
- Damaging‐agent sensitivity of Artemis‐deficient cell linesEuropean Journal of Immunology, 2005